sur VALBIOTIS (EPA:ALVAL)
Valbiotis and Nestlé Health Science terminate their licensing agreement
The company Valbiotis announced the end of its licensing and supply contract with Nestlé Health Science. This agreement, concluded on June 4, 2024, allows Valbiotis to recover all rights to its food supplement, TOTUM•63.
From now on, Valbiotis can launch TOTUM•63 in France in the first half of 2025 and plan international partnerships. The company disposes of the intellectual property, including patents and clinical data, without reimbursement of the 12.75 million Swiss francs paid by Nestlé Health Science.
With cash of 25 million euros at the end of 2023, Valbiotis plans to strengthen its commercial strategy for TOTUM•63. This newfound freedom allows the company to negotiate new licensing agreements and target new markets.
At the same time, Valbiotis continues to develop its other products, such as TOTUM•854 for blood pressure and TOTUM•448 for fatty liver.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de VALBIOTIS